部份中文普鲁士兰处方资料（仅供参考）
商品名：RADIOGARDASE
英文名：Prussian Blue
中文名：普鲁士兰胶囊
生产商：住友制药
药品简介
Radiogardase（Prussian Blue）胶囊是唯一一种治疗被放射性铯（Cs-137）内部污染的人的药物。通过将这种循环路径从胃肠道中敲除并通过粪便排出，阻断了Cs-137的肠肝吸收。
ラディオガルダーゼカプセル500mg
药用类别名称
解毒药
批准日期：2010年12月
商標名
RADIOGARDASE
一般名称: 赫苏里亚诺铁 (II) 铁 (III) 水合物
化学名称: 铁 (III) 六角酯 (II)
结构式:
注) x=14~16
分子式: Fe4[Fe(CN)6]xh2o(x=14~16)
分子量:85 9.23 (作为脱水水合物)
性质: 蓝紫色颗粒的结晶性粉末。
操作注意事项
如何打开容器:
由于此代理容器的容器的盖是子锁, 因此它通过以下过程打开。
步骤 1: 用力按下盖子。
第2步: 在按压时拧紧盖子。
批准条件
·减少放射性铯的内部污染
用和化合物中毒
由于该制剂的临床经验有限, 我们对制造和销售后使用该制剂的所有病例进行绩效调查, 尽可能掌握信息, 并收集有关该制剂安全性和有效性的数据, 采取必要措施, 正确使用本制剂。
药用药理学
<放射性セシウムの排泄促進作用>
在大鼠体内施用放射性铯 (137Cs) 时, 当该制剂在放射性铯给药、血液、肝脏、肾脏、脾脏、股骨和全身放射性降低后立即口服11天。
<タリウムの排泄促進作用>
放射性 (204Tl) 在大鼠体内静脉注射, 当药物给药9天时, 放射性中积累的粪便增加, 身体保留率下降。<タリウムの排泄促進作用><放射性セシウムの排泄促進作用>
适应症
·减少放射性铯的内部污染
·用和化合物中毒
用法与用量
通常情况下, 一次6粒 (3g作为六角铁(II)水合物)每天口服三次。应根据患者的病情、年龄和体重进行调整。
临床结果
<健康成人における放射性セシウムの排泄促進作用)>
在7名摄入放射性铯 (137K:37kbq) 的健康成年人中, 当每天三次施用1.0-G剂时, 放射性铯的生物半衰期平均值从94天缩短到31天。
<ゴイアニアにおける放射性セシウムの被曝事故)>
在巴西Goinia 事故中, 该制剂被用于46例, 其中身体受到放射性铯 (137Cs) 的污染。 本制剂 1天3至10g 在成人和年轻成人中, 1至3g本剂1天在儿童中, 口服2, 3或 6次(给药间隔根据剂量调整, 最短 2小时, 每隔2小时服用一次)。在46例中, 对25例放射性铯在给药和停止给药后的生物半衰期进行了观察(表1), 通过给药缩短了放射性铯的生物半衰期。 此外, 该制剂的施用提高了粪便尿中的放射性排泄率。
<タリウム中毒患者におけるタリウム排泄促進作用>
两名中毒患者, 这种1天6g的药物, 分别给药5天或22天。在这两种情况下, 粪便和尿液中的排泄量都有所增加, 脱发等症状得到改善。
此外, 作为一种中毒患者, 该制剂1.5G每天服用3次, 为期2周。因此, 血浓度下降, 感官异常等症状得到改善。
<タリウム中毒患者におけるタリウム排泄促進作用><ゴイアニアにおける放射性セシウムの被曝事故)><健康成人における放射性セシウムの排泄促進作用)>
包装
36胶囊/容器
制造和销售来源
日本介质物理公司
提携
HEYL Chemisch-pharmazeutische Fabrik GmbH & Co.KG
ドイツ
注：以上中文处方资料不够完整，使用者以原处方资料为准。
完整资料附件：http://www.info.pmda.go.jp/go/pack/392900XM1028_1_04/
Notice of acquisition of radioactive cesium removal Agent "Lasdigalidase® Capsules 500mg" approved
-The first domestic introduction of international standard drugs to reduce the internal contamination and efficacy Japan Medi-Physics Co., Ltd. (Head Office: Tokyo Koto-ku, President: Makoto Mikami) is a medicament to reduce the body contamination by radioactive cesium (137Cs, etc.) to the efficacy and effect of the drug "Lasdigalidase® Capsule 500mg" (hereinafter, "
We have obtained the approval of production and sales on October 27.
This agent is a developer and will be released as soon as the sales system is ready by our company to import and sell this agent in Japan by partnering with Hyle (Heyl), a Germany with a proven manufacturing supply in other countries. Radioactive cesium is included in waste materials in nuclear facilities, and there is a risk of radiation exposure in the event of a disaster. It is also one of the radioactive isotopes used extensively in medical (radioactive radiation sources for cancer treatment) and industrial (sterilization and measurement).
In order to reduce internal contamination in the event of radioactive cesium exposure, it is desirable to administer this agent orally within as short a period of time as possible, and it is expected that the stockpile will be promoted in the emergency medical response institutions and disaster base hospitals in Japan. In addition to the Strategic National Stockpile system, the national stockpile has been started United States internationally, and the World Health Organization (WHO) Essential Medicine
　It is regarded as one of the standard radioactive cesium removal agents, such as being raised on the list of stockpile recommendations. On the other hand, in Japan, the Ministry of Health, Labour and Welfare has received a request for introduction from the relevant academic societies at the Conference on the examination of an unapproved drug and an adaptive medicine that requires medical care. It is hoped that the institutional framework to promote the proper stockpiling system will be newly developed from the standpoint of nuclear disaster countermeasures or the National Protection plan.
Our company recognizes the social needs of this agent, and wants to contribute to the nuclear disaster countermeasures in Japan through the supply of this agent. Japan Medi-Physics Co., Ltd. has been engaged in the development, manufacture and supply of high-quality radioactive medicines used in the diagnosis of nuclear medicine, which is useful for early diagnosis of disease. We will continue to contribute to the further development of medical care in Japan those targets. Japan Medi-Physics Co., Ltd. is a joint venture of Sumitomo Chemical Corporation and GE Healthcare (United Kingdom), a leading manufacturer of radioactive pharmaceuticals.
Overview of radioactive cesium Body Removal Agent "Lasdigalidase® Capsules 500mg"　　
Product Name: Japanese name Lasdigalidase® Capsules 500mg
Western Name RADIOGARDASE®
General Name: Japanese name Hexacyano iron (II) acid iron (III) hydrate
Efficacy or efficacy: reduction of internal contamination by radioactive cesium Dosage: Usually, once 6 capsules (3g as Hexaniiron (II) iron (III) hydrate) is administered orally three times a day. In addition, the patient's condition, age, and increase or decrease depending on the weight.